Harmony Biosciences Holdings (HRMY) has appointed Glenn Reicin as Chief Financial Officer and reaffirmed its 2026 net product revenue outlook of US$1.0b to US$1.04b, developments that may influence how investors assess the stock.

The recent CFO appointment and reiterated 2026 revenue outlook come as the share price trades at US$31.05, with a 30 day share price return of 16.99% but a 90 day share price return of 17.60% decline. This suggests short term momentum has picked up after a weaker recent patch, while the 1 year total shareholder return of 5.76% and 3 year total shareholder return of 5.22% decline indicate a mixed longer term picture.

If you are weighing this leadership change against other opportunities in healthcare, it could be a good moment to scan for new ideas among 32 healthcare AI stocks

With the shares at US$31.05, an implied intrinsic discount and a value score of 5 already on the table, the key question now is whether Harmony Biosciences still trades below its true potential or if the market is already pricing in future growth.

Most Popular Narrative: 34.4% Undervalued

With Harmony Biosciences last closing at $31.05 against a narrative fair value of $47.30, the current price sits well below that modeled estimate, which puts extra focus on the financial assumptions behind this gap.

Harmony is positioned to capture new sources of revenue and reduce product concentration risk through near-term late-stage pipeline catalysts, including potential first-to-market launches for ZYN002 in Fragile X syndrome and additional pitolisant formulations (HD and GR), each aimed at high-unmet-need, orphan indications.

Curious what kind of revenue ramp, margin profile, and future earnings multiple are baked into that valuation gap, and how sensitive fair value is to those assumptions.

Result: Fair Value of $47.30 (UNDERVALUED)

However, that potential upside sits alongside real swing factors, including Wakix legal and generic entry risk, and the chance of setbacks in key late stage trials.

Next Steps

With sentiment on Harmony Biosciences clearly mixed, it makes sense to check the underlying data yourself and decide how compelling the upside really looks. To see what the market currently views as the main positives, take a closer look at the 4 key rewards

Looking for more investment ideas?

Do not stop your research with a single stock. Broaden your watchlist using focused screeners that surface opportunities aligned with your own preferences and risk tolerance.

• Target potential mispricings by scanning companies that the market may be overlooking through the 53 high quality undervalued stocks.
• Prioritize balance sheet strength by checking out businesses highlighted in the solid balance sheet and fundamentals stocks screener (43 results).
• Spot lesser known names with solid fundamentals using the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.